See the DrugPatentWatch profile for lurbinectedin

Lurbinectedin, a selective inhibitor of oncogenic transcription, has been associated with certain side effects that have influenced its dosing frequency [1]. The drug is used to treat metastatic small cell lung cancer and has shown promising results; however, its side effects necessitate careful management.

The common side effects of lurbinectedin include neutropenia, leukopenia, anemia, thrombocytopenia, and increased liver enzymes [1]. Neutropenia, a decrease in the number of neutrophils (a type of white blood cell), is the most common side effect and can lead to a weakened immune system, making patients more susceptible to infections. As a result, the dosing frequency of lurbinectedin is often adjusted based on the severity of the neutropenia [1].

The recommended dosing schedule for lurbinectedin is 3.2 mg/m2 administered as a 1-hour intravenous infusion every 21 days until disease progression or unacceptable toxicity [1]. However, if a patient experiences severe neutropenia (ANC < 0.5 x 10^9/L) or febrile neutropenia, the dosing frequency may be reduced to every 28 days [1]. Additionally, if a patient experiences recurrent severe neutropenia, the dosing frequency may be further reduced to every 35 days [1].

In summary, the side effects of lurbinectedin, particularly neutropenia, have influenced its dosing frequency. The drug's recommended dosing schedule is every 21 days; however, the frequency may be adjusted based on the severity of the neutropenia.

Sources:
[1] DrugPatentWatch.com. (n.d.). Lurbinectedin - DrugPatentWatch. Retrieved from <https://www.drugpatentwatch.com/drugs/lurbinectedin>